🎮 DEMO PLAYGROUND - Sample data for demonstration purposes
Trial Portfolio
6 active protocols across 4 sites
| STATUS | PROTOCOL | INDICATION | PHASE | ENROLLMENT | BUDGET | SCREEN FAIL | SITES | |
|---|
| APEX-301 v3.1 | Advanced Non-Small Cell Lung Cancer Apex Therapeutics | PHASE III | 64% 287/450 | 60% $5.1M | 12.8% vs 15.0% | 4 sites | |
| CARDIO-SHIELD-2 v2.0 | Heart Failure with Reduced Ejection Fraction HeartBio Sciences | PHASE II | 71% 142/200 | 60% $2.5M | 16.5% vs 18.0% | 2 sites | |
| METABOFIX-1 v1.0 | Type 2 Diabetes Mellitus Endocrine Solutions Inc | PHASE II | 69% 124/180 | 60% $2.2M | 12.7% vs 15.0% | 2 sites | |
| NEURO-PATH-7 v1.2 | Alzheimer's Disease NeuroScience Corp | PHASE III | 45% 156/350 | 50% $3.5M | 30.4% vs 25.0% | 3 sites | |
| ONCO-BRIDGE-9 v1.0 | Advanced Solid Tumors Bridgeway Oncology | PHASE I | 63% 38/60 | 60% $1.4M | 17.4% vs 20.0% | 2 sites | |
| RESPI-CLEAR-4 v4.0 | Chronic Obstructive Pulmonary Disease PulmoTech Pharmaceuticals | PHASE II | 35% 52/150 | 50% $1.5M | 46.4% vs 20.0% | 1 sites | |